GE Future Medecine

8/2/2019 GE Future Medecine

http://slidepdf.com/reader/full/ge-future-medecine 1/12

GE Healthcare

Financial Analyst Meeting

July 2004

18

Technologies Bio-Sciences

Molecular Diagnostics

Information Technology

Pharmaceutical Solutions

Imaging and Intervention

GE Healthcare:

A Unique Collection Of Expertise…

…Driving Personalized Healthcare



GE Healthcare


July 2004

19

Time for a Fundamental Change…

50% Die After 1st

Heart Attack

Heart Disease

One Person in Three

Will Have Cancer

Cancer

20% Aged 75-84 Suffer From

Alzheimer’s Disease

Brain Disorders



GE Healthcare


July 2004

20

A New Age of Medicine…

21st

Century Personalized Healthcare

Predict Diagnose Inform Treat



GE Healthcare


July 2004

21

Predict: Early Knowledge of Potential

Disease> Genomics Determining

Disease Before Onset> Genomics Determining

Molecular Characterization

of Disease

> Genomics Driving

Theranostics

GE Imaging + Bio-Sciences…Real Differentiators



GE Healthcare


July 2004

67

Protein Separations

Reagents and Purification

Systems for Bio-pharmaceuticals

Applying Bio-Sciences in

Personalized Healthcare

Medical Diagnostics

Contrast Agents and

Radiopharmaceuticalsto Enhance Imaging of

Anatomy, Organs,

Tissue and Cells, and

Molecular Activity

> Double Digit Revenue & OM Growth

> Integrated Customer Approach

> Pharmaceutical Profit Margins

GE Healthcare Bio-Sciences:3 World Class Businesses in Robust Markets

Discovery Systems

Integrated Systems

Used in Drug Discovery& Development

$1.9

~$3.1

2000 2005E

Sales($B) 10%

CAGR



GE Healthcare


July 2004

71

$0.5

~$0.8

Discovery Systems: Role in Clinical

Diagnostics and Drug Discovery> Tools for Understanding

Cellular and Sub-Cellular

Processes

> Genomics, Proteomics andBioassays

> Partnership with Academia,Pharma and Molecular Diagnostics

> Technologies for Tomorrow’sDiagnostics

2000 2005E

Industry Size: ~$13B

Industry Growth: 5-7%

Sales ($B)



GE Healthcare


July 2004

72

Protein Separations: Highly Profitable

Global Franchise with Solid Growth> Tools for Development and

Manufacturing of

Biopharmaceuticals

> Used in 90+% of FDA-approvedBiopharmaceuticals

> Drive Customer Efficiency andReduce Time to Market

> Competitive Edge

– Global Franchise

– Large Installed Base

– Regulatory Barriers to Entry

$0.3

~$0.6

2000 2005E

Industry Size: ~$4B

Industry Growth: 10-12%

Sales ($B)

15%CAGR

15%CAGR



GE Healthcare


July 2004

73

1 9

9

2

1 9

9

3

1 9

9

4

1 9

9

5

1 9

9

6

1 9

9

7

1 9

9

8

1 9

9

9

2 0

0

0

2 0

0

1

2 0

0

2

2

0 0

3

e

2

0 0

4

e

2

0 0

5

e

2

0 0

6

e

0

40

80

120

160

200

Bioprocess sales (£MM)

No of approved

biopharmaceuticals

Researchers and Bio-Pharma Companies

Need Large Quantities of Pure Proteins

for Drug R&D… and More for Production

Genomics & Proteomics

• DNA Analysis• Protein Analysis

Bio-Assays

• Analyze potential drugsfor safety

Production Separations• Manufacturing

Development &

Clinicals

Commercial &

Manufacturing

Research &Discovery

GEHC Biosciences Key Technologies

30% of 500 ongoing

clinical trials are for biopharmaceuticals.

Protein

Separations

DiscoverySystems

Drug DevelopmentProcess

Demand for DS/PS Offerings Driven by

Rapid Growth of Life Sciences & Bio-Pharma



GE Healthcare


July 2004

74

Application and GEHC Products

Genotyping

Diagnostic Imaging

Innovative targeteddiagnostics

PharmacogenomicProfiling

Drug DevelopmentBioRx Manufacture

Objectiveassessment of drugimpact

MegaBACE

CodeLink

Visipaque,Myoview

FDG/PET,

DatSCAN

CodeLink

IN Cell

MabSelect

Sepharose

FDG/PET

GE Solutions at Every Stage

Genetic Predisposition

Treatment

Monitoring and prevention

Treatment selection

Treatment monitoring

Future Model

Better Patient Outcomes

Safer treatments

Cost-effective healthcare

Diagnose

The Role of GEHC Bio-Sciences in

Driving Personalized HealthcareIllness

Symptom-based Diagnosis

Treatment

Recover or revisit

Current Model

Costly and ineffective

Most drugs only work in

33% of patients

Rx side effects are aleading cause of death inthe U.S.



GE Healthcare


July 2004

76

Visit your doctor with illnessVisit your doctor with illness

SymptomSymptom--based diagnosisbased diagnosis

(In Vitro Diagnostics, Imaging)(In Vitro Diagnostics, Imaging)

Recover or revisitRecover or revisit

TreatmentTreatment

Evolving Medical Practice – 20th Century

Empirical Medicine



GE Healthcare


July 2004

77

Better targeted diagnosticsBetter targeted diagnostics(In Vitro Diagnostics, Imaging)(In Vitro Diagnostics, Imaging)

Look for genetic links to diseaseLook for genetic links to disease

TreatmentTreatment

Monitoring and preventionMonitoring and prevention

Treatment selectionTreatment selection

Treatment monitoringTreatment monitoring

(In Vitro Diagnostics, Imaging)(In Vitro Diagnostics, Imaging)

Evolving Medical Practice – 21st Century

Personalized Healthcare



GE Healthcare


July 2004

80

Predict: The Importance of

Genetics and GenomicsGenetics Determining Disease Risk

> Genotyping Individuals, Segment Population Into Risk Groups

Genomics Determining Molecular Characterization Of Disease

> New Way Of Classifying Disease> Improved Detection, Staging And Prognosis> Disease Subtypes (HIV, Antibiotic Resistance)> Therapy And Dose Selection

Genomics Driving Theranostics> Diagnostic Tests Will Become Increasingly Important In The

Selection Of Therapeutics

The Importance Of Proteomics

DNA RNA Protein

GE Future Medecine

Documents

Transcript of GE Future Medecine